Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChronIA trial of morning versus evening tofacitinib XR dosing in inflammatory arthritis
2021-004131-84Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tofacitinib in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (2 arms), sponsored by Erasmus MC. Primary endpoint: Change in self-reported disease activity by RAPID-3. Started Sep 2021; status: active.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2021-004131-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004131-84.